À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.
Supporters of the Canadian Heart Health Strategy and Action Plan continue to solicit support from physicians and the public for a comprehensive strategy for improving Canadian's heart health at both the provincial and federal level.
Edmonton, AB - The steering committee for an ambitious and expensive plan to radically reduce cardiovascular events in Canada now says it hopes to convince politicians in Ottawa to formally consider its proposal by the end of 2009, the chair of the committee, Dr Eldon Smith (University of Calgary, AB), said at the Canadian Cardiovascular Congress 2009.
As previously reported by heartwire, the Canadian Heart Health Strategy (CHHS) and Action Plan [1] is a package of federal and provincial proposals for reducing cardiovascular disease and improving heart health for all Canadians. Supporters of the plan, which include the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada, say the CHHS would cost $700 million over the next seven years but save Canada's economy over $20 billion in direct and indirect costs by 2020.Read full article »
Inside: Prevention
Accredited educational programs,
supported by industry, developed by theheart.org
Variations on chromosome 4q25 are associated with atrial fibrillation (AF). If you had a family history of AF, would you be tested? Dr. Christopher Granger who has such a personal history underwent testing. He discusses the role of genetics in the management of patients with or at risk for AF.
The 2008 AHA meeting included a special session on "Personalized Genomics: Ready for Prime Time?" Read Dr Wang's article on recent genetic findings in CAD, AF and HF while Drs Ballantyne, Granger, Herrington, Mega and Topol address related AHA presentations and the clinical utility of genetic data in CVD management.
The following test-and-teach case is an educational activity modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and will then read evidence-based information that supports the most appropriate answer choice. Please note that these questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the case, there will be a short post-test assessment based on material covered in the activity.
Genetic findings that affect the course of diseases have been increasing geometrically. Cardiology is one of the specialties that has benefited from recent discoveries. David Danar, MD, Scientific Director, MedscapeCME, interviewed John P. Kane, MS, MD, PhD, about the role of genetics in determining the risk for and management of heart disease.
The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS
Join Drs Topol, Califf, Hollenberg and Levy has they list the latest cardiovascular clinical trials demonstrating a genetically targeted response to treatment.
In our first program Drs Gibbons, Holmes, and Simari discuss cell therapy and the latest trials in intervention. Our second program features Drs Gibbons, Ackerman, and Redfield discuss personalized genomics and heart failure.
A national survey shows that although the majority of state Medicaid programs offer coverage for some form of tobacco-dependence treatment, most fall far short of a stated mandate to provide unrestricted access to approved therapies.
The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.
More discussion about the J-curve in hypertension is published this week; one expert believes the undue attention being paid to this subject might discourage doctors from treating high blood pressure aggressively.
In keeping with all the other evidence showing no effects of homocysteine-lowering with B vitamins, the FAVORIT study now confirms that this lack of benefit is also seen in renal-transplant recipients.
Long work shifts with nighttime on-call duty, with the inevitable interruptions of sleep, are associated with ECG, blood-pressure, and biochemical changes associated with increased cardiovascular risk, suggests a randomized crossover study that hints at a sustained effect on the risk markers if the 24-hour shifts happen too frequently.
UPDATED // An 1126-patient trial shows that SPECT and CAC scoring imaging tests are independent and complementary predictors of short- and long-term cardiac risk, respectively.
A synergistic approach of educating general practitioners about hypertension control together with a program to send lay workers into people's homes to educate them about the management of high blood pressure has proven successful in low- to middle-income households in Pakistan.
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumes—the more commonly seen end point with MRI.
The protective effects of diet modification, exercise, and other lifestyle changes against new-onset diabetes showcased in the three-year Diabetes Prevention Program continued out to 10 years in a follow-up analysis.
Two well-known observational registries highlight such changes in women and men over a decade or more: Do women younger than 55 still have an advantage over men in the same age group?
The role of lipids in women for primary prevention of cardiovascular disease is a challenging issue for all providers. Join Drs. Foody, Mora, and Welty as they discuss limitations to current risk stratification models, recent clinical trial data, and the changing paradigm in the management of lipids in women.
We know there are sex and biological differences in the manifestation of CVD. How do these pathophysiological differences affect the diagnosis and treatment of our female patients? Drs. Hayes, Johnson, Manson, and Piña provide their insight.
Despite increased awareness of CVD in women, contemporary studies demonstrate gender differences in outcomes. Differences in age and comorbidities account for some, but not all of these disparities. Join Dr. Foody as she discusses these issues with Drs. Mieres and Redberg.
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
Drs. Hayes and Foody and a committee of experts address the gaps and correct the misconception that CVD is more common in men than women.